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NPHS2 R229Q functional variant is associated with microalbu-
minuria in the general population.
Background. Microalbuminuria is a risk factor for de-
veloping end-stage renal disease and cardiovascular events.
Mutations in NPHS2 have been shown to cause autosomal-
recessive nephrotic syndrome. Recently, a functional polymor-
phism of this gene (R229Q) was described and associated with
a maturity-onset form of nephrotic syndrome. We have investi-
gated whether the carrier status of this novel genetic variant is
associated with microalbuminuria in individuals from the gen-
eral population.
Methods. Demographic, cardiovascular risk factors, and re-
nal phenotypes in 1577 individuals from a cross-sectional–based
study were collected following the general guidelines of the
WHO-MONICA project (monitoring trends and determinants
in cardiovascular diseases). Blood and urine samples were
obtained. Microalbuminuria was determined using a semiquan-
titative protocol, and DNA was extracted from peripheral
lymphocytes.
Results. A strong association was found between the 229Q
allele and microalbuminuria (P = 0.008). The presence of the
229Q allele was still associated with a 2.77-fold increased risk
of presenting microalbuminuria even after adjustment for age,
ethnicity, hypertension, obesity, and diabetes in a multiple lo-
gistic regression model. In addition, a statistically significant
interaction was identified between the presence of the 229Q
allele and body mass index (BMI) (P = 0.01), suggesting an ad-
ditive effect between the 229Q allele and other risk factors for
microalbuminuria.
Conclusion. These data have important implications for the
understanding of microalbuminuria in the general population
and may contribute to better ways of disease prediction and
prevention.
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Podocin is a membrane protein member of the stom-
atin family. It is expressed in the podocytes and has
an important role in the maintenance of the kidney
glomerular capillary permselectivity. Its function is ap-
parently exerted through interactions with other pro-
teins, such as nephrin, also physiologically involved in the
maintenance of podocyte function, namely the adequate
function of the slit diaphragm membrane [1]. Podocin
itself has been shown to localize to the slit diaphragm [2].
The gene expressing podocin, NPHS2, has recently
been cloned. Mutations in NPHS2 can cause nephrotic
syndrome, transmitted in an autosomal-recessive man-
ner, with a histopathologic appearance of focal and
segmental glomerulosclerosis (FSGS) [3]. This type of
nephrotic syndrome usually is diagnosed in preschool
children, but a late-onset form has recently been de-
scribed in patients who are compound heterozygotes,
with one allele harboring a relatively common R229Q
variant [4]. This 229Q variant, present in approximately
4% of Western populations, encodes a protein with lower
affinity for binding to nephrin. However, there are no
studies to date focusing on the late consequences of 229Q
heterozygosity.
It has now been clearly demonstrated that microalbu-
minuria is a risk factor for developing end-stage renal
disease (ESRD) and cardiovascular events. Microalbu-
minuria can also be considered a risk factor for develop-
ing diabetic nephropathy. In hypertensive patients, it is
considered a marker of organ damage [5]. Nevertheless,
little is known about the molecular determinants of this
condition.
We have tested whether the R229Q functional poly-
morphism heterozygosity can contribute to the appear-
ance of microalbuminuria in the general population. In
order to answer this question we have studied the associ-
ation of the NPHS2 R229Q polymorphism with different
renal phenotypes in a large, ethnic heterogeneous, urban
population.
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METHODS
Study population
A cross-sectional study of risk factors for cardiovas-
cular diseases was performed in the urban population of
Vitoria, Brazil, following the general guidelines of the
WHO-MONICA project [6]. A sample of 2044 individu-
als (from an eligible population of 137,330) of both sexes,
aged 25 to 64 years, was invited to participate in the study.
The subjects were chosen after a random selection of
domiciles. In each residence only one subject was invited
according to the nearest birthday.
From this sample, 1577 attended the clinic visit and
were evaluated for height, weight, smoking habits, blood
pressure measurements, and use of medicines. Blood and
urine samples for determination of plasma cardiovascu-
lar risk factors (blood glucose, total cholesterol, lipopro-
tein fractions, and triglycerides) were collected after a
12-hour fasting period. All measurements were per-
formed according to standard techniques.
During the clinic visit all subjects were also submitted
to a racial classification according to a validated question-
naire for the Brazilian population [7, 8]. Subjects were
classified as European descent or African descent accord-
ing to a set of phenotypic characteristics (skin color, hair
texture, shape of the nose, aspect of the lip, and jaw posi-
tion). On the basis of these characteristics, mulattos are
considered racially mixed subjects.
Diabetes mellitus was defined as fasting glucose
>125 mg/dL. Obesity was defined as a body mass index
(BMI) above 30 kg/m2. Overweight was defined as a BMI
between 25 and 29.9 kg/m2.
The study protocol was approved by the Institutional
Review Board of the Espirito Santo Federal University,
and all participants read and signed an approved in-
formed consent.
Blood pressure phenotype determination
Blood pressure was measured by trained technicians
using a standard mercury sphygmomanometer on the left
arm after 5 minutes’ rest with the subject in the sitting po-
sition. The first and fifth phase of Korotkoff sounds were
used for systolic and diastolic blood pressure, respec-
tively. Systolic and diastolic blood pressure was calculated
from two readings taken by two different observers. The
two measurements were obtained with a minimal inter-
val of 10 minutes. Hypertension was defined as the mean
systolic blood pressure of ≥140 mm Hg and/or diastolic
blood pressure of ≥90 mm Hg [9]. Pulse pressure was the
difference between systolic and diastolic blood pressures.
Data on antihypertensive drug use (16.7% of individu-
als) were not included in the definition of hypertensive
individuals because only 30% of these treated subjects
had normal blood pressure. Conservatively, these were
classified as normotensive, and the remaining ones were
included as hypertensive individuals.
Renal phenotype determination
We determined serum urea and creatinine by stan-
dard techniques. Creatinine clearance was calculated in
all participants using the formula of Cockroft and Gault
[10]. Calculated creatinine clearance was standardized to
1.73 m2 of body surface area. Mild renal dysfunction was
defined as a calculated creatinine clearance of 60 mL/
min/1.73 m2 or less [11]. Urine was collected from all pa-
tients overnight (7 p.m. to 7 a.m.) and stored at room
temperature. A sample was separated the same day to
determine albumin concentration by a semiquantitative
assay using a commercial kit (Micral-Test II, Boehringer
Mannheim, Mannheim, Germany) designed to detect al-
bumin concentrations from 2 to 20 mg/dL. Individuals
with albumin concentration higher than 2 mg/dL in urine
were considered positive for microalbuminuria.
Assessment of NPHS2 R229Q genotype
The 5-mL blood samples were drawn into tubes con-
taining EDTA. Genomic DNA was extracted from pe-
ripheral leukocytes using standard techniques. NPHS2
exon 5 was polymerase chain reaction (PCR)-amplified
using the following primers: F 5′-AGGATTTACCAC
AGGATTAAGTTGTGCA – 3′ and R 5′-TAGCTATG
AGCTCCCAAAGGGATGG – 3′. Three microliters of
unpurified PCR product were diluted to 10 lL in rec-
ommended restriction buffer containing 5 U of ClaI and
digested at 37◦C overnight. The PCR products were visu-
alized by electrophoresis in a 3% agarose gel with ethid-
ium bromide and stored in digital form.
Quality control for these assays was assessed by ran-
domly selecting 50 samples to be regenotyped by two
independent technicians.
Statistical analysis
Allele and genotype frequencies among study partic-
ipants were analyzed with the Chi-square test and mul-
tivariate logistic regression using the statistical package
StatView for Windows, version 5.0 (SAS Institute, Inc.,
Cary, NC, USA). Correction for multiple comparisons
was not performed in any of the analyses in the present
study. To test for differences in various characteristics,
Student t test was used for continuous variables and the
Chi-square test was used for categorical variables.
Hardy-Weinberg equilibrium for the distribution of
genotypes was estimated by the Chi-square test. The odd
ratios (OR) for different association models were calcu-
lated with 95% confidence interval (CI) and two-tailed
P values.
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Table 1. Population characteristics per genotype
R229R R229Q P value
Number 1.491 85
Age years 44.9 (10.9) 43.5 (10.7) 0.26
Male% 45.4 47.7 0.69
Systolic blood pressure 127.99 (22.0) 127.21 (19.5) 0.75
mm Hg
Diastolic blood pressure 84.21 (14.1) 84.16 (11.9) 0.97
mm Hg
Pulse pressure mm Hg 43.78 (13.8) 43.05 (13.2) 0.63
Hypertension% 33.7 37.2 0.51
BMI 26.30 (4.9) 26.02 (4.2) 0.61
WHR 0.88 (0.09) 0.88 (0.09) 0.57
Overweight% 36.9 39.5 0.84
Obesity% 19.7 16.3 0.51
Smoking status% 22.2 20.9 0.67
Cholesterol mg/dL 214.88 (48.1) 206.07 (40.6) 0.10
Triglycerides mg/dL 138.06 (128.8) 129.79 (111.2) 0.56
HDL-cholesterol mg/dL 45.30 (12.4) 46.47 (12.2) 0.40
LDL-cholesterol mg/dL 142.67 (39.9) 134.47 (33.5) 0.06
Glucose mg/dL 105.08 (32.1) 103.39 (30.9) 0.64
Diabetes% 8 4.7 0.27
Abbreviations are: BMI, body mass index; WHR, waist hip ratio. Data are
presented as mean (standard deviation). Diabetes mellitus was defined as fasting
blood glucose >125 mg/dL.
Logistic regression analysis that allowed for age, sex,
diabetes mellitus, ethnicity, obesity, and hypertension ex-
plored the association between genotype and risk of mi-
croalbuminuria.
P values less than 0.05 on a two-sided test were consid-
ered significant.
RESULTS
In the 1577 individuals investigated in this study we
found 85 heterozygous individuals for the R229Q sub-
stitution and one individual homozygous for this allele.
Allele frequency was 2.76%, which is in accordance with
previous findings. Allele and genotype frequencies were
in Hardy-Weinberg equilibrium (P = 0.99). Interestingly,
a tendency toward an increased frequency of individuals
harboring the 229Q allele was found in Caucasian indi-
viduals, as compared with both mulatto and black indi-
viduals (6.9% in the European descent group, 4.9% in the
mulatto group, and 2.5% in the African descent group;
P = 0.18). For all further analysis we excluded the
229Q homozygous individual and compared genotype-
phenotype associations regarding heterozygosity for the
R229Q variant.
Population characteristics per genotype are presented
in Table 1. We were able to collect complete phenotypic
information regarding microalbuminuria on 1027 indi-
viduals. There was no significant difference between the
samples of individuals with and without urinary albumin
excretion data regarding the main demographic predic-
tors of microalbuminuria. No significant difference was
present between any of the studied variables and the pres-
ence of the 229Q allele. Renal phenotypes per genotype
Table 2. Renal phenotypes and R229Q allele
R229R R229Q P value
Serum urea mg/dL 27,34 (10,0) 27,85 (7,6) 0.64
Serum creatinine mg/dL 0,97 (0,2) 0,97 (0,2) 0.81
Creatinine clearance mL/mina 89,40 (25,6) 90,75 (24,6) 0.63
Mild renal dysfunciton%b 9.76 8.14 0.62
Microalbuminuria% 6.11 14.75 0.008
aEstimated by the formula of Cockroft and Gault.
bEstimated creatinine clearance <60mL/min.
Table 3. Logistic regression model for presence of proteinuria
Variable OR 95% CI P value
Diabetes 4.6 2.33–9.06 <0.0001
Overweight 2.99 1.51–5.93 0.002
Obesity 3.27 1.53–6.95 0.002
Hypertension 1.39 0.80–2.43 0.25
Age 0.98 0.95–1.00 0.09
Ethnicity 0.94 0.74–1.18 0.57
Presence of R229Q allele 2.77 1.21–6.34 0.02
are presented in Table 2. No significant difference regard-
ing creatinine clearance and the presence of the 229Q al-
lele was observed. Nevertheless, 9 out of 61 individuals
(14.8%) with the 229Q allele presented with microalbu-
minuria, a significantly different figure from the one ob-
served in individuals without the 229Q allele; only 59 out
of 966 (6.1%) individuals presented a positive semiquan-
titative measurement of microalbuminuria (P = 0.008).
In order to better study the association between the
presence of the 229Q allele and presence of albuminuria
we have constructed multiple logistic regression models
seeking variables associated with significant albuminuria
in our sample. These data are presented in Table 3. The
presence of the 229Q allele was still associated with a 2.77-
fold increased risk of presenting microalbuminuria even
after adjustment for age, ethnicity, hypertension, obesity,
and diabetes.
In addition, a statistically significant interaction was
identified between the presence of the 229Q allele and
both BMI, as a continuous variable (P = 0.01), and obe-
sity, as a dichotomous variable (P = 0.008), suggesting
an additive effect between the 229Q allele and other risk
factors for microalbuminuria (Fig. 1). Although the pres-
ence of the R229Q allele does not significantly increase
the risk of microalbuminuria in non-obese individuals, it
is associated with an increasingly higher risk of microal-
buminuria in obese individuals.
DISCUSSION
ESRD is a major health concern. In the United States
the total estimated cost for Medicare patients with ESRD
in 1998 was $12.04 billion, and it is estimated that by 2010
there will be 651,330 long-term ESRD patients [12].
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Fig. 1. Chance of microalbuminuria in percentage relative to R229Q
genotype and a body mass index (BMI) >27. Groups were compared
using the Chi-square test.
Although a number of primary kidney diseases may
lead to ESRD, the majority of cases are secondary,
namely due to diabetic and hypertensive nephropathies.
Despite a number of proposed treatment and measures
to delay progression to this condition, little is known re-
garding their molecular determinants of susceptibility.
Here we show for the first time that the presence of
the 229Q allele of the NPHS2 gene, recently identified as
a cause of autosomal-recessive late-onset nephrotic syn-
drome and present with an allele frequency of 4% con-
trol populations, is associated with an increased risk of
microalbuminuria in the general population. Presence of
this allele was still significantly associated with a 2.77-fold
increased risk of microalbuminuria even after adjustment
for confounders such as age, blood pressure, obesity, di-
abetes, and ethnicity.
Several lines of evidence indicate that microalbumin-
uria is a valuable surrogate marker for both disease mor-
bidity and mortality. In diabetes it has been shown that
individuals presenting microalbuminuria have an en-
hanced risk of developing progressive renal failure com-
pared with subjects with a normal albumin excretion [13].
It has been suggested that the same situation may also
be operant in hypertension [14]. In addition, it has been
shown that microalbuminuria enhances the risk for car-
diovascular mortality in diabetic patients [13] and in pa-
tients with essential hypertension. Finally, it has recently
been published that an increased albumin excretion is
also associated with increased mortality even in the gen-
eral population [15].
Even though microalbuminuria is considered a marker
of renal and cardiovascular morbi-mortality, questions
regarding a real causative role of proteinuria are still
highly debatable. Either way, our findings should con-
stitute highly useful information. If, on the one hand, mi-
croalbuminuria is really a cause of increased morbidity
and progression to ESRD or cardiovascular mortality,
then identification of individuals at increased risk of this
condition can prove to be of major public health impor-
tance. If, on the other hand, microalbuminuria is only a
confounding marker for increased disease mortality, then
knowledge of genetic risk factors associated with a “be-
nign microalbuminuria” should be incorporated into al-
gorithms of risk stratification.
Besides showing an increased risk of microalbumin-
uria, our data also suggest that comorbidities such as obe-
sity may further help to unmask the deleterious effect of
this allele regarding microalbuminuria. This fact may sug-
gest that physical factors such as blood flow may have an
important role in the cascade of pathologic events leading
to loss of podocyte homeostasis and proteinuria. It also
may point toward important targets for disease preven-
tion and individualization of renoprotective treatments.
Our study has some potential limitations. The method-
ology used for identifying individuals with microalbumin-
uria was based on a semiquantitative protocol. Although
this approach may, at first, be considered less sensitive
or less specific, our data show highly concordant figures
when compared with studies that relied upon quantitative
methods of microalbuminuria measurement [16]. In ad-
dition, important predictors of microalbuminuria, such as
age, obesity, and diabetes, were also associated with this
phenotype in our population, further validating it as a ro-
bust variable. Finally, the protocol used may also detect
proteinuria above 200 mg/L and we cannot completely
exclude the presence of individuals with macroalbumin-
uria in our sample. However, one would not expect a
great number of individuals with macroalbuminuria in a
sample randomly selected from the general population
with no known renal disease.
CONCLUSION
A better understanding of the role of the R229Q func-
tional variant regarding progression to ESRD and occur-
rence of cardiovascular events will not only shed light in
unknown aspects of podocyte and glomerular physiology,
but constitutes an important tool in disease prediction
and prevention.
NOTE ADDED IN PROOF
Patent pending for the use of this gene variant in
disease prevention, risk assessment, and renoprotective
treatments.
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